International: +1-347-960-6455
Diarrhoea Therapeutics - Pipeline Analysis 2018

Diarrhoea Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10023 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Gastroenterology
Select License Type

Diarrhoea involves loose, frequent, and watery bowel movements, caused by gastrointestinal infections, medicines, and irritable bowel syndrome. Rotaviruses are the most common viral causative agents for this. Based on duration, diarrhoea is categorized into three types; acute diarrhoea, persistent diarrhoea, and chronic diarrhoea. Dehydration and malabsorption are some complications associated with diarrhoea. A person with diarrhoea generally goes through cramping, irregular bowel movements, nausea, and abdominal pain. In case diarrhoea is caused by an infection, bloody stools, vomiting, fever and chills, and dizziness are some symptoms that are observed in a patient. Scandinavian Biopharma AB is in the process of developing ETVAX for the treatment of diarrhoea caused by ETEC – an enteric bacteria responsible for hundred thousand of deaths annually among children in low- to middle income countries.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.